No difference in serum uric acid level reduction rate using febuxostat depending on type of hyperuricemia (retrospective study in actual clinical practice)

Abstract

We retrospectively investigated the rate of change in serum uric acid levels after administering 10 mg of febuxostat in 397 male patients with hyperuricemia and gout, who were classified by clearance tests as the 216 with the uric acid underexcretion type, 126 with the renal overload type, 38 with the combined type, and 17 with the normal type. In patients with the uric acid underexcretion type, serum uric acid levels significantly decreased from 8.9 ± 1.2 to 6.9 ± 1.0 mg/dL, with a reduction rate of 22.3 ± 8.8%. The rates of decrease in serum uric acid levels after administration of 10 mg of febuxostat in patients with renal overload, combined, and normal types were 22.4 ± 8.9%, 22.0 ± 11.8%, and 17.0 ± 7.4%, respectively, not being significantly different from the rate of decrease in patients with the uric acid underexcretion type. In 580 male patients with hyperuricemia and gout receiving the selective uric acid reabsorption inhibitor dotinurad, administration of 0.5 mg of dotinurad reduced serum uric acid levels from 8.6 ± 1.2 to 6.8 ± 1.3 mg/dL, with a reduction rate of 21.4 ± 10.1%. There was no difference in the rate of decrease in serum uric acid levels with 10 mg of febuxostat depending on the type of hyperuricemia, and the rate of decrease in serum uric acid level was equivalent to that with 0.5 mg of dotinurad.